文献速递瓣膜外科

透析患者二尖瓣置换术中的假体选择

Prosthesis Choice in Dialysis Patients Undergoing Mitral Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2023-05-26

回顾性分析2002年1月至2019年11月单中心177例透析依赖患者二尖瓣置换术,其中生物瓣118例(66.7%)、机械瓣59例(33.3%);两组5年死亡风险调整后无显著差异,机械瓣组卒中更多(15% vs 6%,P=.041),两组结构性瓣膜退化或再干预率无差异,结论认为透析患者二尖瓣置换术并发症和中期死亡率高,预期寿命缩短应在假体选择时予以考虑。

要点

  • 透析患者二尖瓣置换术后早期死亡率高,两组2年生存率均低于50%。
  • 机械瓣组随访卒中事件多于生物瓣组(15% vs 6%,P=.041)。
  • 两组5年死亡风险调整后无显著差异(P=.668),结构性瓣膜退化或再干预率无差异。

核心结论

  • 透析患者二尖瓣置换术并发症和中期死亡率高,预期寿命缩短应在假体选择时予以考虑。

研究设计与样本

  • 回顾性分析2002年1月至2019年11月单中心成人二尖瓣置换术患者,纳入既往有肾功能衰竭和透析需求的177例透析患者,按机械瓣与生物瓣分组比较。

主要发现

  • 177例透析患者中,118例(66.7%)接受生物瓣,59例(33.3%)接受机械瓣。
  • 机械瓣组较生物瓣组年轻(48岁 vs 61岁;P < .001),糖尿病比例较低(32% vs 51%;P = .019)。
  • 两组感染性心内膜炎和心房颤动患病率相似,术后住院时间无差异。
  • 两组5年死亡风险调整后无显著差异(P = .668);早期死亡率高,两组2年 actuarial 生存率均低于50%。
  • 两组结构性瓣膜退化或再干预率无差异;机械瓣组随访卒中事件更多(15% vs 6%;P = .041);感染性心内膜炎是再干预的主要原因,4例因生物瓣失败再次手术。

临床怎么用

  • 原文结论认为透析患者二尖瓣置换术并发症和中期死亡率高,预期寿命缩短应在假体选择时予以考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with renal disease on dialysis have significant comorbidity limiting life expectancy; however, these patients may experience accelerated prosthetic valve degeneration. The purpose of this study was to examine the impact of prosthesis choice on outcomes in dialysis patients undergoing mitral valve replacement (MVR) at our high-volume academic center. METHODS: Adults undergoing MVR were retrospectively reviewed between January 2002 and November 2019. Patients were included if they had documented renal failure and dialysis requirements before presentation. Patients were stratified by mechanical vs bioprosthetic prosthesis. Death and recurrent severe valve failure (3+ or greater) or redo mitral operation were used as primary outcomes. RESULTS: There were 177 dialysis patients identified who underwent MVR. Of these, 118 (66.7%) received bioprosthetic valves, whereas 59 (33.3%) received mechanical valves. Those who received mechanical valves were younger (48 vs 61 years; P < .001) and had less diabetes (32% vs 51%; P = .019). Prevalence of endocarditis and atrial fibrillation was similar. Postoperative length of stay was not different between groups. Risk-adjusted hazard for 5-year mortality was similar between groups (P = .668). Early mortality was high, with both groups having <50% actuarial survival at 2 years. No differences were noted in rates of structural valve deterioration or reintervention. More stroke events were noted on follow-up in patients receiving mechanical valves (15% vs 6%; P = .041). Endocarditis was the leading reason for reintervention; 4 patients received repeated surgery for bioprosthetic valve failure. CONCLUSIONS: MVR in dialysis patients carries significant morbidity and increased midterm mortality. Decreased life expectancy should be considered in the tailoring of prosthesis choice to dialysis-dependent patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Iyengar A, Song C, Weingarten N, et al. Prosthesis Choice in Dialysis Patients Undergoing Mitral Valve Replacement. Ann Thorac Surg. 2023. PMID: 37245789. doi:10.1016/j.athoracsur.2023.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。